Cargando…
Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemical...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087479/ https://www.ncbi.nlm.nih.gov/pubmed/32257197 http://dx.doi.org/10.3892/mco.2020.2014 |
_version_ | 1783509338363527168 |
---|---|
author | Fohlin, Helena Bekkhus, Tove Sandström, Josefine Fornander, Tommy Nordenskjöld, Bo Carstensen, John Stål, Olle |
author_facet | Fohlin, Helena Bekkhus, Tove Sandström, Josefine Fornander, Tommy Nordenskjöld, Bo Carstensen, John Stål, Olle |
author_sort | Fohlin, Helena |
collection | PubMed |
description | Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)-positive/progesterone receptor (PR)-negative tumors with high Ras-related protein Rab-6C (RAB6C) expression levels (RAB6C(+)) had prolonged distant recurrence-free survival compared with that of patients exhibiting low RAB6C (RAB6C(-))-expressing tumors. The aim of the present study was to investigate whether RAB6C predicts the effectiveness of tamoxifen treatment. The present study used a dataset comprising 486 female patients with ER(+) tumors from a randomized study conducted by the Stockholm Breast Cancer Study Group between November 1976 and August 1990. The patients were considered as low-risk if their tumor size was ≤30 mm and their lymph node status was negative. Patients were followed up until distant recurrence, mortality or when 25 years after randomization was achieved, whichever occurred first. For patients with ER(+)/PR(-)/RAB6C(+) tumors, prolonged distant recurrence-free survival could not be observed if the patients were treated with tamoxifen [hazard ratio (HR), 1.82; 95% confidence interval (CI), 0.69-4.79; P=0.23], whereas patients with ER(+)/PR(-)/RAB6C(-) tumors had 75% reduced distant recurrence risk (HR, 0.25; 95% CI, 0.09-0.70; P=0.008). In the ER(+)/PR(+) subgroup, patients with RAB6C(-) and RAB6C(+) tumors benefited from tamoxifen treatment, though it was most evident in the RAB6C(+) group (HR, 0.27; 95% CI, 0.13-0.58; P=0.001). The results of the present study indicated that, for patients with ER(+)/PR(-) tumors, those with low RAB6C expression benefited from tamoxifen treatment, whereas no benefit was observed in patients with high RAB6C levels. |
format | Online Article Text |
id | pubmed-7087479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-70874792020-04-02 Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer Fohlin, Helena Bekkhus, Tove Sandström, Josefine Fornander, Tommy Nordenskjöld, Bo Carstensen, John Stål, Olle Mol Clin Oncol Articles Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)-positive/progesterone receptor (PR)-negative tumors with high Ras-related protein Rab-6C (RAB6C) expression levels (RAB6C(+)) had prolonged distant recurrence-free survival compared with that of patients exhibiting low RAB6C (RAB6C(-))-expressing tumors. The aim of the present study was to investigate whether RAB6C predicts the effectiveness of tamoxifen treatment. The present study used a dataset comprising 486 female patients with ER(+) tumors from a randomized study conducted by the Stockholm Breast Cancer Study Group between November 1976 and August 1990. The patients were considered as low-risk if their tumor size was ≤30 mm and their lymph node status was negative. Patients were followed up until distant recurrence, mortality or when 25 years after randomization was achieved, whichever occurred first. For patients with ER(+)/PR(-)/RAB6C(+) tumors, prolonged distant recurrence-free survival could not be observed if the patients were treated with tamoxifen [hazard ratio (HR), 1.82; 95% confidence interval (CI), 0.69-4.79; P=0.23], whereas patients with ER(+)/PR(-)/RAB6C(-) tumors had 75% reduced distant recurrence risk (HR, 0.25; 95% CI, 0.09-0.70; P=0.008). In the ER(+)/PR(+) subgroup, patients with RAB6C(-) and RAB6C(+) tumors benefited from tamoxifen treatment, though it was most evident in the RAB6C(+) group (HR, 0.27; 95% CI, 0.13-0.58; P=0.001). The results of the present study indicated that, for patients with ER(+)/PR(-) tumors, those with low RAB6C expression benefited from tamoxifen treatment, whereas no benefit was observed in patients with high RAB6C levels. D.A. Spandidos 2020-05 2020-03-09 /pmc/articles/PMC7087479/ /pubmed/32257197 http://dx.doi.org/10.3892/mco.2020.2014 Text en Copyright: © Fohlin et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Fohlin, Helena Bekkhus, Tove Sandström, Josefine Fornander, Tommy Nordenskjöld, Bo Carstensen, John Stål, Olle Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
title | Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
title_full | Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
title_fullStr | Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
title_full_unstemmed | Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
title_short | Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
title_sort | low rab6c expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087479/ https://www.ncbi.nlm.nih.gov/pubmed/32257197 http://dx.doi.org/10.3892/mco.2020.2014 |
work_keys_str_mv | AT fohlinhelena lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer AT bekkhustove lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer AT sandstromjosefine lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer AT fornandertommy lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer AT nordenskjoldbo lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer AT carstensenjohn lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer AT stalolle lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer |